1.60
price down icon2.44%   -0.04
after-market Handel nachbörslich: 1.63 0.03 +1.87%
loading
Schlusskurs vom Vortag:
$1.64
Offen:
$1.64
24-Stunden-Volumen:
1.99M
Relative Volume:
1.11
Marktkapitalisierung:
$159.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.34M
KGV:
-1.1765
EPS:
-1.36
Netto-Cashflow:
$-36.91M
1W Leistung:
-10.11%
1M Leistung:
-8.05%
6M Leistung:
+44.14%
1J Leistung:
+13.48%
1-Tages-Spanne:
Value
$1.56
$1.655
1-Wochen-Bereich:
Value
$1.56
$1.83
52-Wochen-Spanne:
Value
$0.772
$2.12

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Name
Firmenname
Sellas Life Sciences Group Inc
Name
Telefon
(646) 200-5278
Name
Adresse
7 TIMES SQUARE, NEW YORK, NY
Name
Mitarbeiter
15
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
SLS's Discussions on Twitter

Vergleichen Sie SLS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SLS
Sellas Life Sciences Group Inc
1.60 177.60M 0 -37.34M -36.91M -1.36
Biotechnology icon
ONC
Beone Medicines Ltd Adr
258.27 26.01B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.85 114.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.3499 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
83.98 6.29B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
484.93 63.90B 14.09B 4.50B 2.96B 39.28

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-07-21 Eingeleitet Cantor Fitzgerald Overweight
2018-11-01 Eingeleitet Oppenheimer Outperform
2018-04-02 Eingeleitet H.C. Wainwright Buy
2018-03-19 Hochstufung Maxim Group Hold → Buy

Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten

pulisher
Jun 04, 2025

Northern Trust Corp Acquires 33,878 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

SELLAS reports potential colorectal cancer therapy progress By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

SELLAS reports potential colorectal cancer therapy progress - Investing.com India

Jun 03, 2025
pulisher
Jun 02, 2025

Sellas Life Sciences Group, Inc. Presents Preclinical Efficacy of Sls009 in Asxl1 Mutated Colorectal Cancer At 2025 Asco Annual Meeting - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

SELLAS Life Sciences (SLS) Highlights Promising Results for SLS009 in Cancer Study | SLS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Breakthrough at ASCO: SELLAS Drug Shows Powerful Response in Targeted Colorectal Cancer Treatment - Stock Titan

Jun 02, 2025
pulisher
May 23, 2025

Insider Buying: Katherine Kalin Acquires 20,000 Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus

May 23, 2025
pulisher
May 23, 2025

US futures and global markets tumble after Trump threatens European Union with 50% tariffs and Apple with 25% tariff - The Globe and Mail

May 23, 2025
pulisher
May 22, 2025

Director Makes Bold Move with Major Stock Purchase in SELLAS Life Sciences Group - TipRanks

May 22, 2025
pulisher
May 20, 2025

Sellas Life Sciences Reports Improved Financial Position - TipRanks

May 20, 2025
pulisher
May 20, 2025

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase - The Manila Times

May 20, 2025
pulisher
May 20, 2025

SELLAS Life Sciences CEO to Reveal Latest Cancer Drug Development Strategy at Major Healthcare Conference - Stock Titan

May 20, 2025
pulisher
May 16, 2025

Sellas doses first paediatric subject with AML in Phase II trial of SLS009 - Yahoo Finance

May 16, 2025
pulisher
May 15, 2025

SELLAS advances pediatric AML treatment with Phase 2 trial By Investing.com - Investing.com South Africa

May 15, 2025
pulisher
May 15, 2025

Sellas Life Sciences Doses 1st Pediatric Patient in Acute Myeloid Leukemia Study - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

SELLAS Life Sciences (SLS) Advances Phase 2 Trial for Pediatric AML | SLS Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

SELLAS advances pediatric AML treatment with Phase 2 trial - Investing.com

May 15, 2025
pulisher
May 15, 2025

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

Breakthrough: First Child with Resistant Leukemia Receives New Treatment in Major Clinical Trial - Stock Titan

May 15, 2025
pulisher
May 14, 2025

SELLAS Life Sciences (SLS) Reports Improved Q1 Earnings Amid Fin - GuruFocus

May 14, 2025
pulisher
May 14, 2025

SLS009 Shows Promising Results in Latest AML Trials | SLS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

May 14, 2025
pulisher
May 13, 2025

SELLAS Life Sciences Group Reports Positive Overall Survival Data for SLS009 in r/r AML and Updates on Financial Position and Pipeline Developments - Nasdaq

May 13, 2025
pulisher
May 13, 2025

SELLAS Life Sciences (SLS) Reports Improved Q1 Earnings Amid Financial Boost - GuruFocus

May 13, 2025
pulisher
May 12, 2025

Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.

May 12, 2025
pulisher
May 11, 2025

SELLAS Life Sciences Group (SLS) Expected to Announce Quarterly Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 07, 2025

Upward Trajectory: SELLAS Life Sciences Group Inc (SLS) Posts a Gaine, Closing at 1.72 - DWinneX

May 07, 2025
pulisher
May 02, 2025

Financial Metrics Exploration: Understanding SELLAS Life Sciences Group Inc (SLS) Through Ratios - DWinneX

May 02, 2025
pulisher
May 02, 2025

Geode Capital Management LLC Purchases 128,355 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World

May 02, 2025
pulisher
Apr 30, 2025

Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - Sete News

Apr 30, 2025
pulisher
Apr 29, 2025

SELLAS Life Sciences Group Inc’s latest rating changes from various analysts - knoxdaily.com

Apr 29, 2025
pulisher
Apr 29, 2025

SELLAS Life Sciences Group Inc (SLS) Stock: The Story of a 52-Week Stock Range - investchronicle.com

Apr 29, 2025
pulisher
Apr 29, 2025

Understanding the Risks of Investing in La Rosa Holdings Corp (LRHC) - knoxdaily.com

Apr 29, 2025
pulisher
Apr 28, 2025

SELLAS reports promising AML treatment in preclinical study - Investing.com

Apr 28, 2025
pulisher
Apr 28, 2025

SELLAS Life Sciences (SLS) Reports Promising Preclinical Results for SLS009 in Leukemia | SLS Stock News - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference - The Manila Times

Apr 28, 2025
pulisher
Apr 28, 2025

Breakthrough: New Cancer Drug SLS009 Extends AML Patient Survival by 252% in Clinical Trial Data - Stock Titan

Apr 28, 2025
pulisher
Apr 25, 2025

SELLAS Life Sciences Group Inc: Navigating Market Fluctuations with a 127.18M Market Cap - investchronicle.com

Apr 25, 2025
pulisher
Apr 25, 2025

The time has not yet come to remove your chips from the table: SELLAS Life Sciences Group Inc (SLS) - Sete News

Apr 25, 2025
pulisher
Apr 25, 2025

BILI Shares Experience Surge in Value - knoxdaily.com

Apr 25, 2025
pulisher
Apr 24, 2025

SLSSellas Life Sciences Group Inc Latest Stock News & Market Updates - Stock Titan

Apr 24, 2025
pulisher
Apr 24, 2025

Ratio Review: Analyzing fuboTV Inc (FUBO)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX

Apr 24, 2025
pulisher
Apr 24, 2025

Financial Fitness Check: Examining Royalty Pharma plc (RPRX)’s Key Ratios - DWinneX

Apr 24, 2025
pulisher
Apr 24, 2025

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 1.6% Higher – Time to Buy? - Defense World

Apr 24, 2025
pulisher
Apr 23, 2025

Amazon's Earnings Could Fuel a Rapid Breakout - The Globe and Mail

Apr 23, 2025
pulisher
Apr 23, 2025

SELLAS Life Sciences Group, Inc. to Present Preclinical Efficacy Data for SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025 Annual Meeting - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

Clinical Trial Breakthrough: SELLAS Unveils Novel Cancer Drug Results for Hard-to-Treat ASXL1 Mutations - Stock Titan

Apr 23, 2025
pulisher
Apr 22, 2025

How did SELLAS Life Sciences Group Inc (SLS) fare last session? - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

Analysts review SELLAS Life Sciences Group Inc’s rating - knoxdaily.com

Apr 22, 2025

Finanzdaten der Sellas Life Sciences Group Inc-Aktie (SLS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.16
price up icon 0.00%
$573.50
price down icon 0.54%
$36.08
price up icon 15.90%
$305.31
price up icon 0.51%
$4.75
price up icon 3.70%
$484.93
price down icon 0.60%
Kapitalisierung:     |  Volumen (24h):